24.08.2010 • NewsRocheRoche Holding

Roche Buys Bioimagene for $100 Million, Boosts Diagnostics

Swiss drugmaker Roche Holding is buying U.S. - based Bioimagene for some $100 million, making another bolt-on acquisition to cement its dominant position in tissue-based cancer diagnostics.

Diagnostics is gaining more importance in cancer treatment, which is being increasingly dovetailed to the genetic profile of patients. Roche is the world's largest maker of cancer drugs.

"As part of the personalised healthcare approach, pathologists are increasingly involved in generating information with high impact on treatment decisions," Daniel O'Day, chief operating officer at Roche Diagnostics, said in a statement.

Bioimagene's products create high-resolution, whole-slide digital images from glass microscope slides. The privately held group also provides the software to view, analyse and manage tissue images using a computer.

"We view the bolt-on acquisition as a good complement to the existing offering in tissues diagnostics, which is becoming increasingly important and crucial for personalised therapy options," Kepler Capital Markets analyst Martin Voegtli said in a note.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.